<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02606032</url>
  </required_header>
  <id_info>
    <org_study_id>REB# 0163</org_study_id>
    <nct_id>NCT02606032</nct_id>
  </id_info>
  <brief_title>Trial of Antimicrobials Versus Placebo in Addition to Fecal Transplant Therapy in Ulcerative Colitis</brief_title>
  <acronym>FMT</acronym>
  <official_title>Randomized Trial of Antimicrobials Versus Placebo in Addition to Fecal Microbiota Therapy in for the Induction of Remission in Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hamilton Academic Health Sciences Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hamilton Health Sciences Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will test the hypothesis that giving antibiotics prior to fecal transplant
      therapy for active UC increases the proportion of patients in remission at the end of
      treatment. The investigators will randomize patients aged 18 or over with active UC to
      antibiotics (metronidazole 500mg, doxycycline 100mg, Terbinafine 250 mg, all twice daily for
      two weeks); or identical placebo. At the end of two weeks the investigators will give all
      patients fecal transplant therapy twice per week for eight weeks from the donor whose stool
      showed most efficacy in the trial (donor B). Patients will complete a validated UC
      questionnaire, have a flexible sigmoidoscopy to assess the degree of inflammation in the
      colon and complete general and disease specific quality of life questionnaire as well as a
      questionnaire on anxiety and depression. Patients will complete the same questionnaires again
      at the end of treatment at week 9 when they will also have a repeat flexible sigmoidoscopy.
      The main outcome that will be assessed is the proportion of patients in remission from their
      UC at the end of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients aged 18 or over with active UC defined as a Mayo score &gt; 3 with an endoscopic score
      &gt;0 will be eligible for the study. Subjects will be excluded if they are participating in
      another clinical trial, are unable to give informed consent, have severe comorbid medical
      illness, have concomitant Clostridium difficile infection or have severe UC requiring
      hospitalization. Continued treatment with 5-ASA, azathioprine, 6-mercaptopurine or anti-TNFα
      therapy (e.g. infliximab) will be permitted if taken at stable dose for ≥12 weeks prior to
      randomization. Eligible patients will be randomized 1:1 to metronidazole 500mg bid,
      doxycycline 100mg bid, Terbinafine 250 mg and or identical placebos all for two weeks.
      Patients will all then receive their first FMT 1-3 days after completing their course of
      antibiotic/placebo. The investigators will also use stool from donor B exclusively for
      frozen/thawed FMT as this donor was associated with the most success in the previous trial
      and this will be administered at St Joseph's Hospital under the care of Dr Lee. FMT will be
      administered twice per week for 8 weeks.

      Eighty active UC patients will be randomized 1:1 according to a computer generated
      randomization list. Randomization will be administered centrally at the GI Clinical Trials
      Unit to ensure concealment of allocation.

      Subjects will have a sigmoidoscopy (or colonoscopy if clinically indicated), physician
      assessment and complete a Mayo score, IBDQ questionnaire, EQ5D and HAD questionnaires at
      baseline. A repeat sigmoidoscopy, Mayo score, IBDQ, EQ5D and HAD questionnaires will be
      completed at 9 weeks, at exit from the study (one week after last FMT). No new medical
      therapies (e.g. corticosteroids, antibiotics, probiotics) will be permitted during the 9 week
      study period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome of the randomized trial is remission of UC defined as a Mayo score &lt; 3 with an endoscopic Mayo score = 0 at the end of the trial Transplant Therapy in Ulcerative Colitis</measure>
    <time_frame>9 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Metronidazole+doxycylcine+terbinafine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metronidazole 500 mg BID, Doxycycline 100 mg BID, Terbinafine 250 mg once daily all for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Metronidazole, Placebo Doxycycline, and Placebo Terbinafine all BID for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>active comparator</description>
    <arm_group_label>Metronidazole+doxycylcine+terbinafine</arm_group_label>
    <other_name>Flagyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>active comparator</description>
    <arm_group_label>Metronidazole+doxycylcine+terbinafine</arm_group_label>
    <other_name>Vibramycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbinafine</intervention_name>
    <description>active comparator</description>
    <arm_group_label>Metronidazole+doxycylcine+terbinafine</arm_group_label>
    <other_name>Lamisil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>identical placebos to all antibiotics</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged 18 or over

          2. Active UC defined as a Mayo score &gt; 3

          3. A Mayo endoscopic score &gt; 0

        Exclusion Criteria:

          1. Participating in another clinical trial

          2. Unable to give informed consent

          3. Severe co-morbid medical illness

          4. Concomitant Clostridium difficile infection

          5. Severe UC requiring hospitalization.

          6. Increase in medical therapy for UC in the last 12 weeks. Continued treatment with
             5-ASA, azathioprine, 6-mercaptopurine or anti-TNF alpha therapy (e.g. infliximab) will
             be permitted if taken at stable dose for ≥12 weeks prior to randomization. Relapse on
             a stable dose (same dose for at least 2 weeks) or a tapering dose of steroids will
             also be permitted provided the dose of steroid is not increased again. Stable intake
             of probiotic therapy also permitted.

          7. Antibiotic therapy in the last 30 days.

          8. Pregnant women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Moayyedi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton HSC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Moayyedi, MD</last_name>
    <phone>905-521-2100</phone>
    <phone_ext>76764</phone_ext>
    <email>moayyep@mcmaster.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melanie Wolfe, CCRP</last_name>
    <phone>905-521-2100</phone>
    <phone_ext>73601</phone_ext>
    <email>wolfe@hhsc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamilton Health Sciences / McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Moayyedi, MD</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>76764</phone_ext>
      <email>moayyep@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>Melanie Wolfe, CCRP</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>73601</phone_ext>
      <email>wolfe@hhsc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Moayyedi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Marshall, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Walter Reinisch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hamilton Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2015</study_first_submitted>
  <study_first_submitted_qc>November 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hamilton Health Sciences Corporation</investigator_affiliation>
    <investigator_full_name>Paul Moayyedi</investigator_full_name>
    <investigator_title>Director Division of Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>Fecal Microbiota Transplant</keyword>
  <keyword>Antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terbinafine</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

